vs
PROGRESS SOFTWARE CORP(PRGS)とBio-Techne(TECH)の財務データ比較。上の社名をクリックして会社を切り替えられます
Bio-Techneの直近四半期売上が大きい($295.9M vs $252.7M、PROGRESS SOFTWARE CORPの約1.2倍)。Bio-Techneの純利益率が高く(12.8% vs 10.2%、差は2.7%)。PROGRESS SOFTWARE CORPの前年同期比売上増加率が高い(17.5% vs -6.4%)。過去8四半期でPROGRESS SOFTWARE CORPの売上複合成長率が高い(17.0% vs 4.2%)
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
Bio-Techne社は米国発のライフサイエンス企業で、研究・診断・バイオプロセスの各市場向けに、ライフサイエンス用試薬、機器、各種サービスの開発・製造・販売を事業の柱としています。製品は基礎研究から医薬品開発、体外診断まで多岐にわたる分野で活用されています。
PRGS vs TECH — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | ||
|---|---|---|
| 売上 | $252.7M | $295.9M |
| 純利益 | $25.7M | $38.0M |
| 粗利率 | 81.6% | 64.6% |
| 営業利益率 | 15.2% | 18.4% |
| 純利益率 | 10.2% | 12.8% |
| 売上前年比 | 17.5% | -6.4% |
| 純利益前年比 | 2144.6% | 68.3% |
| EPS(希薄化後) | $0.59 | $0.24 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $252.7M | $295.9M | ||
| Q3 25 | $249.8M | — | ||
| Q2 25 | $237.4M | $317.0M | ||
| Q1 25 | $238.0M | $316.2M | ||
| Q4 24 | $215.0M | $297.0M | ||
| Q3 24 | $178.7M | $289.5M | ||
| Q2 24 | $175.1M | $306.1M | ||
| Q1 24 | $184.7M | $303.4M |
| Q4 25 | $25.7M | $38.0M | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $17.0M | $-17.7M | ||
| Q1 25 | $10.9M | $22.6M | ||
| Q4 24 | $1.1M | $34.9M | ||
| Q3 24 | $28.5M | $33.6M | ||
| Q2 24 | $16.2M | $40.6M | ||
| Q1 24 | $22.6M | $49.1M |
| Q4 25 | 81.6% | 64.6% | ||
| Q3 25 | 81.0% | — | ||
| Q2 25 | 80.1% | 62.7% | ||
| Q1 25 | 80.6% | 67.9% | ||
| Q4 24 | 83.0% | 65.3% | ||
| Q3 24 | 83.7% | 63.2% | ||
| Q2 24 | 81.7% | 66.4% | ||
| Q1 24 | 82.2% | 67.4% |
| Q4 25 | 15.2% | 18.4% | ||
| Q3 25 | 17.6% | — | ||
| Q2 25 | 16.3% | -7.5% | ||
| Q1 25 | 13.6% | 12.2% | ||
| Q4 24 | 10.0% | 16.0% | ||
| Q3 24 | 22.6% | 13.8% | ||
| Q2 24 | 15.5% | 15.0% | ||
| Q1 24 | 19.0% | 22.1% |
| Q4 25 | 10.2% | 12.8% | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 7.2% | -5.6% | ||
| Q1 25 | 4.6% | 7.1% | ||
| Q4 24 | 0.5% | 11.7% | ||
| Q3 24 | 15.9% | 11.6% | ||
| Q2 24 | 9.2% | 13.3% | ||
| Q1 24 | 12.3% | 16.2% |
| Q4 25 | $0.59 | $0.24 | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.39 | $-0.11 | ||
| Q1 25 | $0.24 | $0.14 | ||
| Q4 24 | $0.01 | $0.22 | ||
| Q3 24 | $0.65 | $0.21 | ||
| Q2 24 | $0.37 | $0.26 | ||
| Q1 24 | $0.51 | $0.31 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $94.8M | $172.9M |
| 総負債低いほど良い | $1.4B | $260.0M |
| 株主資本純資産 | $478.3M | $2.0B |
| 総資産 | $2.5B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | 2.93× | 0.13× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $94.8M | $172.9M | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $102.0M | $162.2M | ||
| Q1 25 | $124.2M | $140.7M | ||
| Q4 24 | $118.1M | $177.5M | ||
| Q3 24 | $232.7M | $187.5M | ||
| Q2 24 | $190.4M | $152.9M | ||
| Q1 24 | $133.2M | $145.3M |
| Q4 25 | $1.4B | $260.0M | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | $346.0M | ||
| Q1 25 | $1.5B | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $478.3M | $2.0B | ||
| Q3 25 | $477.7M | — | ||
| Q2 25 | $452.7M | $1.9B | ||
| Q1 25 | $431.8M | $2.0B | ||
| Q4 24 | $438.8M | $2.1B | ||
| Q3 24 | $425.6M | $2.1B | ||
| Q2 24 | $401.7M | $2.1B | ||
| Q1 24 | $461.7M | $2.0B |
| Q4 25 | $2.5B | $2.5B | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | $2.6B | ||
| Q1 25 | $2.5B | $2.6B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.6B | $2.7B | ||
| Q1 24 | $1.5B | $2.7B |
| Q4 25 | 2.93× | 0.13× | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 3.22× | 0.18× | ||
| Q1 25 | 3.50× | 0.16× | ||
| Q4 24 | 3.48× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $62.8M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $59.9M | — |
| FCFマージンFCF / 売上 | 23.7% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | 2.44× | — |
| 直近12ヶ月FCF直近4四半期 | $229.5M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.8M | — | ||
| Q3 25 | $73.4M | — | ||
| Q2 25 | $30.0M | $98.2M | ||
| Q1 25 | $68.9M | $41.1M | ||
| Q4 24 | $19.7M | $84.3M | ||
| Q3 24 | $57.7M | $63.9M | ||
| Q2 24 | $63.7M | $75.5M | ||
| Q1 24 | $70.5M | $81.0M |
| Q4 25 | $59.9M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | $29.5M | $93.3M | ||
| Q1 25 | $67.7M | $31.0M | ||
| Q4 24 | $16.8M | $77.5M | ||
| Q3 24 | $56.6M | $54.7M | ||
| Q2 24 | $62.7M | $57.5M | ||
| Q1 24 | $70.2M | $64.5M |
| Q4 25 | 23.7% | — | ||
| Q3 25 | 29.0% | — | ||
| Q2 25 | 12.4% | 29.4% | ||
| Q1 25 | 28.4% | 9.8% | ||
| Q4 24 | 7.8% | 26.1% | ||
| Q3 24 | 31.7% | 18.9% | ||
| Q2 24 | 35.8% | 18.8% | ||
| Q1 24 | 38.0% | 21.3% |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.5% | 3.2% | ||
| Q4 24 | 1.3% | 2.3% | ||
| Q3 24 | 0.6% | 3.2% | ||
| Q2 24 | 0.5% | 5.9% | ||
| Q1 24 | 0.2% | 5.4% |
| Q4 25 | 2.44× | — | ||
| Q3 25 | 3.78× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 6.30× | 1.82× | ||
| Q4 24 | 17.13× | 2.42× | ||
| Q3 24 | 2.03× | 1.90× | ||
| Q2 24 | 3.93× | 1.86× | ||
| Q1 24 | 3.11× | 1.65× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |